Creo Medical Group PLC
LSE:CREO
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Creo Medical Group PLC
LSE:CREO
|
UK |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Al-Dawaa Medical Services Co
SAU:4163
|
SA |
|
M
|
Middle East Specialized Cables Company SJSC
SAU:2370
|
SA |
|
Yangtze Optical Fibre and Cable Joint Stock Ltd Co
SSE:601869
|
CN |
|
K
|
Kerjaya Prospek Group Bhd
KLSE:KERJAYA
|
MY |
|
R
|
Riyadh Cables Group Company CJSC
SAU:4142
|
SA |
|
E
|
Evolution AB (publ)
LSE:0RQ6
|
SE |
|
Union Bank of India Ltd
NSE:UNIONBANK
|
IN |
|
S
|
Sunrise Group Co Ltd
SZSE:002752
|
CN |
|
Pan Pacific International Holdings Corp
OTC:DQJCY
|
JP |
Creo Medical Group PLC
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
